Whitepaper: Early product characterisation mitigates risks in biologics development
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
List view / Grid view
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
Readily deployable, fully integrated mobile testing labs for fast-track delivery of diagnostic and analytical lab capability where and when needed.
The use of flexible mobile biocontainment and test units to prevent the spread of transmissible diseases.
A stability study that provides an opportunity to extend the product shelf life, by optimising the formulation and/or product packaging.
Learn how Process Analytical Technology (PAT) and real-time TOC testing of pharmaceutical grade water systems can improve efficiency.
See how compliant products, unique packaging and smart labels make EMSURE® inorganics and solvents the smartest choice for pharmaceutical analysis.
Medicines and other healthcare products rely for their value, integrity and commercial longevity on a delicate balance between quality, safety and efficacy.
Supel™ BioSPME 96-Pin Devices vastly outperform current sample preparation techniques for plasma protein binding studies and free fraction analyses.
Monitoring headspace oxygen to ensure stability and potency of finished oxygen sensitive product.
G-CON’s standard POD maximises efficiencies in production, qualification and cost and eliminates the complexity of cleanroom construction projects.
GEA’s digitally-enabled process optimisation tools improve the customer experience and expedite the successful completion of pharmaceutical research, development and production projects. This comprehensive suite of process simulations, digital twins, augmented/virtual reality systems and remote support solutions represents a safe and effective environment in which to achieve operational excellence, expedite FATs,…
Outlining the most common comments from drug manufacturers, the Parenteral Drug Association (PDA) and US Food and Drug Administration (FDA) on the USP draft chapter for recombinant Factor C ().
In this ebook, discover innovative solutions for three core areas of drug development: drug formulation, scale-up and analysis with hot melt extrusion; quality control and validation using microscopic and spectroscopic instruments; and instrumentation for nucleic acid quantification and qualification.
The BIOshell™ superficially porous particle (SPP) packed columns aid research to understand the subtleties of the molecule being developed.
The Discovery® BIO wide pore reversed-phase HPLC columns and capillaries provide sensitive, stable, efficient and reproducible separations.